NCT05033756
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05033756
Title Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO (COMPRENDO)
Acronym COMPRENDO
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Institut fuer Frauengesundheit
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
Department of Gynecology, Tübingen University Hospital Tübingen Baden-Wurttemberg 72076 Germany Details
University Hospital Ulm Ulm Baden-Wurttemberg 89075 Germany Details
Department of Gynecology and Obstetrics, Erlangen University Hospital Erlangen Bavaria 91054 Germany Details
Marienhospital Bottrop Bottrop North Rhine-Westphalia 46236 Germany Details
University Hospital Düsseldorf Düsseldorf North Rhine-Westphalia 40225 Germany Details
Helios-Klinikum Berlin-Buch Berlin 13125 Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field